Clinical trial

Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute…

NCT00369317 · Children's Oncology Group, Other · Completed

Key facts

NCT number NCT00369317
Title Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
Official title The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Lead sponsor Children's Oncology Group, Other
Collaborators National Cancer Institute (NCI) NIH
Status Completed
Phase Phase 3
Study type Interventional
Conditions Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Leukemia, Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Minimally Differentiated Myeloid Leukemia (M0), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4) and 5 more
Intervention type Drug, Other
Interventions asparaginase, daunorubicin hydrochloride, cytarabine, thioguanine, etoposide, laboratory biomarker analysis
Enrollment 205
Start date Mar 1, 2007
Primary completion Dec 1, 2013
Completion Dec 31, 2021
First posted Aug 29, 2006
Last update posted Jan 28, 2022
Countries Australia, Canada, Puerto Rico, United States

At a glance

  • 10–99 Study sites
  • Yes Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies